• 1
    Corte's-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 2007; 7: 5660.
  • 2
    Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007; 8: 10391058.
  • 3
    Deng S, Wojnowskil L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 2007; 7: 129134.
  • 4
    Menna P, Recalcati S, Cairo G, Minotti G. An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007; 7: 8085.
  • 5
    Lal S, Mahajan A, Chen WN, Chowbay B. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 2010; 11: 115128.
  • 6
    Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538549.
  • 7
    Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH, Guo JY, Lim R, Yap HL, Khoo YM, Iau P, Lee HS, Lee SC. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics 2008; 18: 623631.
  • 8
    Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010; 102: 10031009.
  • 9
    Lal S, Wong ZW, Sandanaraj E, Xiang X, Ang PCS, Lee EJD, Chowbay B. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 2008; 99: 816823.
  • 10
    Jin Y, Penning TM. Aldo-ketoreductases and bioactivation/detoxification. Annu Rev Pharmacol Toxicol 2007; 47: 263292.
  • 11
    Veitch ZW, Guo B, Hembruff SL, Bewick AJ, Heibein AD, Eng J, Cull S, Maclean DA, Parissenti AM. Induction of 1C aldo-ketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet Genomics 2009; 19: 477488.
  • 12
    Bains OS, Grigliatti TA, Reid RE, Riggs KW. Naturally occurring variants of human aldo-ketoreductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther 2010; 335: 533545.
  • 13
    Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012; 30: 14221428.
  • 14
    Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PC, Figg WD, Lee EJ, Chowbay B. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 2007; 8: 567575.
  • 15
    Andersen A, Warren DJ, Slørdal L. A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther Drug Monit 1993; 15: 455461.
  • 16
    James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999; 91: 523528.
  • 17
    Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. PNAS 2010; 107: 92879292.
  • 18
    Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383391.
  • 19
    Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I. The Pharmacogenetics Research Network: from SNP Discovery to Clinical Drug Response. Clin Pharmacol Ther 2007; 8: 328345.
  • 20
    Lennard I, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1987; 7: 18161823.
  • 21
    Rodman JH, Abromowitch M, Sinkule JA, Hayes FA, Rivera GK, Evan WE. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 1987; 5: 10071014.
  • 22
    Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10: 520528.
  • 23
    Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M, Sinkule JA. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther 1989; 45: 340347.
  • 24
    Ma B, Yeo W, Hui P, Ho WM, Johnson PJ. Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer- a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 2002; 62: 185189.
  • 25
    Beith JM, Goh BC, Yeo W, Sullivan A, Lim S, Zhong S, Rivory LP. Inter-ethnic differences in the myelotoxicity of adriamycin/ cyclophosphamide (AC) or adjuvant breast cancer. Proc Am Soc Clin Oncol 2002; 21: abstract 252.